Navigation Links
K94 Discoveries, Inc. Announces Seed Financing To Advance Targeted Drug Conjugates To Treat Pancreatic And Other Cancers
Date:9/24/2013

BATON ROUGE, La., Sept. 24, 2013 /PRNewswire/ -- K94 Discoveries, Inc., (K94) a new biotechnology company applying hormone receptor-targeting technology to develop novel cancer therapies, today announced that it has closed a $300,000 seed financing. The financing was provided by BVM Capital, LLC, through its Themelios Ventures II, LP fund.  Ross P. Barrett, Managing Partner of BVM Capital, is interim President of the new company.

K94 Discoveries is developing cancer therapies based on proprietary hormone receptor-targeting discoveries by scientific founder William Hansel, Ph.D., a Professor at the William Hansel Cancer Prevention laboratory at the Pennington Biomedical Research Center of Louisiana State University (LSU). Dr. Hansel found that the luteinizing hormone-releasing hormone (LHRH) receptors present in large numbers on the surface of a wide variety of cancer cells can be harnessed to target cancer drugs.  A version of this technology is also embodied in the targeted cancer drugs being developed by Esperance Pharmaceuticals, a clinical-stage company partly based on Dr. Hansel's inventions

K94 researchers are using a similar approach to develop targeted drug conjugates by combining LHRH with the naturally-occurring plant extract curcumin, which has attracted interest as a potential anticancer agent for decades.  Preclinical studies indicate that curcumin exhibits multiple anticancer properties, and in laboratory tests it promotes cancer cell death and slows the growth of tumors.  However, curcumin's therapeutic potential has been limited by its poor solubility, which the company's novel drug conjugates are designed to overcome.  K94 is initially focusing on pancreatic cancer and is also conducting research in ovarian and breast cancer.

"We are fortunate in Louisiana to have access to extraordinary scientists such as Dr. Hanse
'/>"/>

SOURCE K94 Discoveries, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015  Delays in the launch and execution ... the decision-making process, resulting in missed opportunities and ... biopharmaceutical companies to develop a tactical approach to ... and more meaningful insights. According ... three-quarters of benchmarked study participants use review cycle ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Originally discovered by ... Yoshitomi Pharmaceutical Industries, Ltd) as an inflammatory drug, ... Senju Pharmaceutical Co., Ltd under the trade name ...
(Date:8/28/2015)... , Aug. 28, 2015 ... addition of the "Investigation Report on China,s Tobramycin ... Tobramycin is a traditional antibiotic whose eye drop and ... treatment of potential infection or inflammation caused by eye ... are able to produce tobramycin, among which ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Pranoprofen Market, 2010-2019 2Investigation Report on China's Tobramycin Market, 2015-2019 2
... N.Y., Oct. 25, 2011 Misonix, Inc. (NASDAQ: ... that designs, manufactures and markets innovative therapeutic ultrasonic ... surgery, neurosurgery, laparoscopic surgery, and other surgical and ... the BoneScalpel™ Ultrasonic Bone Cutting System at the ...
... HIGHLIGHTS:2011 Results (all percentages are to comparable periods in 2010) ... to $626 million. Q3 sales grew organically by 4% with ... 4% and 2%, respectively.  Recently completed acquisitions contributed an additional ... additional 5% to reported sales growth in Q3. ...
Cached Medicine Technology:Misonix Exhibits BoneScalpel™ at the International Meeting on Advanced Spine Techniques 2Misonix Exhibits BoneScalpel™ at the International Meeting on Advanced Spine Techniques 3Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 2Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 3Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 4Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 5Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 6Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 7Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 8Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 9Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 10Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 11Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 12Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 13
(Date:8/28/2015)... , ... August 28, 2015 , ... ... or those who might personally be struggling with chemical dependency, may be able ... Best Drug Rehabilitation, a results-driven holistic treatment center for addiction located in Western ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... Library for documenting and diagramming network and data center assets and audio-video devices, ... Device Model, Cisco Nexus 5000 Series, HP ProLiant Gen9, EMC VNX Series , ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Nashville ... military veterans leading in business. Mr. Troy Mizell, Chairman of the Board ... Nashville Business Journal's 2015 Veterans Awards will recognize Nashville military veterans who, through ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... loyalty at a low cost. Personalized with practice contact information and logos, Calendars ... Dental offices can also incorporate Calendars into seasonal mailings, thank you and welcome ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... Mendon, IL, ... of good music and good people, all for a good cause. In its second ... 2015, sponsored once more by Best Drug Rehabilitation. The “Mission” of “Music With A ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3Health News:MyGenetx Board Member Receives Veterans Award 2Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2
... ... One online magazine and website, www.usariseup.com , provides a forum to have an ... ... the heated debates raging over immigration, America,s multi-racial, multi-ethinic society is still the foundation ...
... for suspected pulmonary embolism test negative, researchers find , TUESDAY, ... necessary in many patients suspected of having a blood clot ... identify those most likely to require the procedure, a new ... clot, usually from the leg, moves through the bloodstream and ...
... ... Medical Genetics to meet virtual repository technology needs of the network, , ... Reston, VA (PRWEB) June 15, ... American College of Medical Genetics (ACMG) has selected the company to contribute web-based applications ...
... ... “Learn More” series , ... NY (PRWEB) June 15, 2010 -- VoIP Supply, North America’s leading supplier of Voice over ... Buyers Guide . The VoIP Phone Buyers Guide is the second guide to be released ...
... ... York-based tutoring , testing and coaching center Brain Academy has once again helped a ... learning. Brain Academy,s unique focus on cognitive improvement is not only academically effective, but ... subjects. , ...
... ... Enthusiastically Embrace Any Innovation That Enables Them To Fit The Care Of Their Parents Into ... ... person over the age of 65 will need some form of long term care during ...
Cached Medicine News:Health News:Why A Multi-Racial, Multi-Ethnic Society Needs Open and Sustained Dialogue 2Health News:Why A Multi-Racial, Multi-Ethnic Society Needs Open and Sustained Dialogue 3Health News:Docs Should Assess Lung Clot Risk Before Ordering Scan 2Health News:Technology Innovation Advances Newborn Screen Translational Research Network 2Health News:Technology Innovation Advances Newborn Screen Translational Research Network 3Health News:VoIP Supply Releases VoIP Phone Buyers Guide 2Health News:Brain Academy's Revolutionary New Approach to Tutoring and Test Prep Helps Students Find Academic Success 2Health News:Brain Academy's Revolutionary New Approach to Tutoring and Test Prep Helps Students Find Academic Success 3Health News:Brain Academy's Revolutionary New Approach to Tutoring and Test Prep Helps Students Find Academic Success 4Health News:Brain Academy's Revolutionary New Approach to Tutoring and Test Prep Helps Students Find Academic Success 5Health News:Online Services Will Energise The Country's Invisible Healthcare Service 2Health News:Online Services Will Energise The Country's Invisible Healthcare Service 3
... RNA Mini Kit allows purification ... cell-free fluid samples. Examples of ... be isolated with this kit ... to, RNA from hepatitis A, ...
The Mago® Plus Automated EIA Analyzer is a fully automated, integrated ELISA system. Together, with immunosimplicity® reagents, the Mago® Plus provides a flexible, integrated solution ...
... computer-enhanced microplate reader with a ... flexible and rapid photometric analysis. ... and reliable photometric measurement of ... shaking before reading) and can ...
The Rapidpoint 400/405 instrument is a point-of-care blood gas analyzer that's fast, easy to operate and reliable....
Medicine Products: